Steven M. Larson, MD
Nuclear Medicine Physician
Hedvig Hricak Chair in Radiology; Attending, Molecular Imaging and Therapy Service, Department of Radiology; Member and Lab Head, Molecular Pharmacology Program
General Nuclear Medicine; Radiolabeled Antibodies for Tumor Imaging and Therapy; Positron Emission Tomography; Radioisotopic Therapy for Thyroid Cancer
New Patient Appointments
Scheduling a visit is easy. Click below or call us to get started.
Dr. Larson accepts the following list of insurance providers. Select your insurance provider to see more details.
Memorial Sloan Kettering is an in-network provider with Aetna HMO, POS, and PPO plans. Aetna does not include us in any of the plans you can purchase through the insurance exchanges or through Medicare. Please ask your insurance if you need a one-time referral. MSK has an agreement with the Aetna Transplant Program for all Aetna's commercial products.
Memorial Sloan Kettering is a designated Blue Distinction Center for bone marrow transplant and CAR-T.
We understand that there may be many complexities involved with insurance coverage purchased through the health exchange network of the Affordable Care Act. We’re here to help. If you have questions about how your care will be covered by an insurance provider, or need help navigating a change in coverage, please call us at 646-227-3378; if you are not a resident of New York, you can call us at 866-248-1274. Our team is here to listen to your concerns and assist you in any way we can. We want our care to be as accessible and affordable for as many people as possible.
Memorial Sloan Kettering is an in-network provider with CIGNA's HMO, POS, and PPO plans. CIGNA does not include us in any of the plans you can buy through the insurance exchanges.
- If you are a New York State resident: Please ask your insurance if you need a one-time referral.
- If you live outside of New York State: Please ask your insurance if you have in-network access to Memorial Sloan Kettering.
Memorial Sloan Kettering is an in-network provider with EmblemHealth’s PPO, EPO, POS, HMO plans. EmblemHealth includes GHI, HIP, Vytra, and ConnecticCare (in NYS Only). You must bring a referral from your Emblem primary care doctor to your first appointment. In-network participation exceptions include:
- Emblem’s HIP Commercial Millennium, Select Care and Enhanced Care Prime networks is not in-network with Memorial Sloan Kettering.
- Please call Emblem to confirm if your specific plan is in-network.
For information regarding Memorial Sloan Kettering’s participation with Emblem’s Medicare Advantage Plans, please refer to the Medicare & Medicaid page
Memorial Sloan Kettering is an in-network provider with Empire Blue Cross Blue Shield (Wellpoint) of New York Indemnity, HMO, EPO, PPO, POS and Medicare Advantage plans, with the following exceptions:
- Empire Blue Cross Blue Shield does not include us in any of the plans you can buy through the insurance exchanges.
- Please call Empire BCBS to confirm if your specific plan is in-network with Memorial Sloan Kettering.
Memorial Sloan Kettering is an in-network provider with HealthFirst’s commercial products; these commercial products are not purchased on the insurance exchanges.
Memorial Sloan Kettering is an in-network provider with HealthSmart’s Accel, HSPC, and HPO networks.
For our NJ locations, Memorial Sloan Kettering is an in-network provider with most Horizon Blue Cross Blue Shield of New Jersey plans for individuals, families, and small businesses. Horizon members with Blue Card Access (there would be a suitcase logo on the front of the card) may have access to our NY locations. Please call Horizon to confirm if your plan is in-network in NY.
Memorial Sloan Kettering is a designated Center of Excellence by Humana.
Memorial Sloan Kettering is a designated Center of Excellence by Interlink Health Services.
Memorial Sloan Kettering is a designated Center of Excellence by Lifetrac.
Memorial Sloan Kettering is an in-network provider for all MagnaCare health plans except those products you can buy through the insurance exchanges.
For information about Medicare and Medicaid, please visit this page
Memorial Sloan Kettering is an in-network provider with some Multiplan/Beech Street/PHCS plans. Contact your insurance carrier to find out if your plan provides in-network access to Memorial Sloan Kettering.
Memorial Sloan Kettering is a designated Center of Excellence by Multiplan.
If you are covered by more than one insurance plan, you will want to determine your benefits from both plans. First, you need to determine which one is your primary insurance provider by contacting your employee benefits office or your insurance carriers. After you find out which is your primary insurance provider, you should then contact your insurance carrier to determine if you have access to Memorial Sloan Kettering.
Memorial Sloan Kettering is an in-network provider with some MVP plans. Contact your insurance carrier to find out if your plan provides in-network access to Memorial Sloan Kettering.
Memorial Sloan Kettering is an in-network provider for New York State employees who have enrolled in UnitedHealthcare's Cancer Resource Services. If you have the Empire Plan, you should call Cancer Resources Services at 866-936-6002 to verify and enroll in this coverage.
Memorial Sloan Kettering is in-network with Oscar’s Circle Plus Network, a part of its Small Group Broad line that is offered only to select small business groups. Oscar does not include Memorial Sloan Kettering as an in-network provider for any of its individual plans. Please confirm eligibility with your insurance carrier.
Most Blue Cross Blue Shield plans include Memorial Sloan Kettering as an in-network provider. Contact your insurance company to confirm if Memorial Sloan Kettering is in-network.
We have agreements with several insurance companies that may provide additional coverage for cancer patients. These benefit programs include:
- AXA Assistance USA
- Beech Street
- Integrated Health Plans
- National Health Administrators
- National Preferred Provider Network
- UnitedHealthcare's Cancer Resource Services
- United Resource Network
- Veterans Choice Program
Memorial Sloan Kettering is an in-network provider with Oxford’s Freedom and Liberty plans as well as the Metro Plan (which is only offered to small business groups and no longer offered as individual plans). Please confirm with your insurance if you need a one-time referral. Note: Oxford’s Medicare Managed Care plan — Secure Horizon — does not include Memorial Sloan Kettering as an in-network provider. Oxford does not include us in any of the plans you can buy through the insurance exchanges.
Memorial Sloan Kettering is an in-network provider with the World Trade Center Health Program.
Memorial Sloan Kettering is an in-network provider with QualCare's PPO and HMO/POS network.
Memorial Sloan Kettering is a designated Center of Excellence by Specialty Care Management.
Hospital and physician services may be covered by TRICARE. Please call your TRICARE plan to confirm coverage at Memorial Sloan Kettering.
Memorial Sloan Kettering is an in-network provider with UnitedHealthCare's HMO, POS, and PPO plans. Please confirm with your insurance if a one-time referral is needed.
UnitedHealthCare's Medicare Managed Care plan does not include Memorial Sloan Kettering as an in-network provider.
United does not include us in any of the plans you can buy through the insurance exchanges.
Memorial Sloan Kettering is a designated Center of Excellence by UnitedHealthcare.
Contact and Location
Memorial Sloan Kettering has locations throughout New York City, Long Island, New Jersey, and Westchester. These locations offer many services, including screening, chemotherapy, and medical testing.
MD, University of Washington School of Medicine (Seattle)
Virginia Mason Hospital (Seattle)
National Institutes of Health
Nuclear Medicine; Internal Medicine
I am a board-certified nuclear medicine physician who cares for patients using radiotargeted therapy, particularly for people with thyroid cancer. My clinical interests focus on the use of positron emission tomography (PET) for diagnostic and molecular imaging, as well as targeted therapy and theranostics. At Memorial Sloan Kettering, I use radioantibodies and PET in oncologic imaging, both for basic research and patient management.
While an undergraduate at the University of Washington (UW) in Seattle, I worked as a radiochemistry technician in a radiobiology laboratory monitoring plants and animals for radioactive fallout from atmospheric atom bomb testing. This experience instilled in me a lifelong interest in radiochemistry and the effects of radiation.
In medical school at UW, I invented the first successful “kit” formulation introduced into nuclear medicine, 99mTc-Sulder colloid, a radiopharmaceutical that is still widely used in nuclear medicine today.
Prior to joining MSK, I served as Chief of Nuclear Medicine at the Clinical Center of the National Institutes of Health, where I developed a PET program focused on brain research, including brain tumors and cancer molecular imaging. I also directed and developed nuclear medicine and PET programs at Veterans Administration Hospitals in Portland and Vancouver, the University of Oregon in Portland, and Seattle Veterans Administration Hospital. I co-authored several highly cited papers on Alzheimer’s disease and AIDS dementia and collaborated on early studies of PET-FDG in brain tumor imaging, including treatment response.
I also served as a second lieutenant in the Public Health Services at the National Institutes of Health (NIH) and as an assistant professor at Johns Hopkins School of Medicine. While at Hopkins, I helped develop a novel method still in use for detection and susceptibility testing for mycobacterium species, including mycobacterium tuberculosis.
I have served as a member of what is now the Medical Imaging (MEDI) grant review committee of the NIH, the Department of Energy Office of Science Advisory Committee, and the American Board of Nuclear Medicine. I’ve also served as Chair of the Radiopharmaceutical Advisory Committee of the FDA, Co-Chair of a National Research Council of the National Academy of Sciences Committee on Molybdenum-99 production with non-enriched Uranium 235, and Chair of the Molecular Imaging Committee of the Radiological Society of North America. I am currently Chair of the Clinical Imaging Steering Committee of the National Cancer Institute and of the Clinical “Impact” Study Section of NIH, as well as a member of the National Academy of Medicine.
I have received numerous awards for excellence in nuclear medicine, including the Hevesy Award from both the Society of Nuclear Medicine and Molecular Imaging (SNM) and the European Society of Nuclear Medicine; the Shaw prizes and the Wagner Lecture Award from SNM; the Pendergrass Award and the Radiologic Researcher of the Year Award from the Radiological Society of North America; and the Cassen Prize. I have also received the Wiley Medal from the FDA for distinguished service, in recognition of co-developing with FDA colleagues the concept of Radioactive Drug Research Committee, which is an active regulation used throughout the United States. I have also published more than 500 peer-reviewed publications in prestigious journals.
- Clinical Trials Co-Investigated by Dr. Larson
- [18F]-Deoxy-D-Glucose (FDG) and [18F] Dihydro-Testosterone PET Imaging in Patients with Progressive Prostate Cancer
Memorial Sloan Kettering's doctors and scientists are constantly developing new treatments for cancer. MSK is typically running hundreds of clinical trials at a given time.
You may be able to participate in a clinical trial even if you are new to MSK. Search our online directory to find trial information and see more about who can participate.
Research and Publications
Visit PubMed for a full listing of Dr. Larson’s journal articles. Pubmed is an online index of research papers and other articles from the US National Library of Medicine and the National Institutes of Health.
Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.
MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.
Steven M. Larson discloses the following relationships and financial interests:
Samus Therapeutics LLC
Intellectual Property Rights
Ownership / Equity Interests
Y-mAbs Therapeutics, Inc.
Intellectual Property Rights; Ownership / Equity Interests
If you’re a patient at MSK and would like more information about your doctor’s external relationships, please talk with your doctor.
The information published here is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.
This page and data include information for a specific MSK annual disclosure period (January 1, 2020 through disclosure submission in spring 2021). This data reflects interests that may or may not still exist. This data is updated annually.